根据弗若斯特沙利文数据分析，全球寡核苷酸药物市场规模从2016年0.1亿美元增长至2021年32.5亿美元，年复合增长率高达217.8%。根据Evaluate和BCG分析，2026年全球寡核苷酸市场规模将达到150亿美元（约合人民币1067亿元）。

Several ASX companies are conducting clinical trials, and this has become a valuable sector and an asset to the Australian ...

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

Increased funding and new public health policies for sickle cell research are needed to ease the burden on low-income nations ...

Here we report the use of C5-propynyl-dU,dC-phosphorothioate antisense oligonucleotides to inhibit IGF-I receptor expression in keratinocytes. We identified several inhibitory antisense ...

Tominersen is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in Huntington Disease.

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the ...